© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Latest Conference Articles
On Topical Steroid Withdrawal Syndrome, We Need Bigger Studies, More Clinical Trials: Brad Glick, DO, MPH
June 18th 2025
Revolutionizing Atopic Dermatitis (RAD)
The literature on topical steroid withdrawal syndrome is scant, Glick says; we're learning more about it, but we need more research to help our patients.
The Future of Atopic Dermatitis Management: Peter Lio, MD, on Preparing for Next-Generation Treatment Strategies
June 17th 2025
Revolutionizing Atopic Dermatitis (RAD)
RAD 2025: Peter Lio, MD, discussed the benefits of disease-specific meetings, the evolving AD landscape, and why continuity across sessions enhances clinician education.
Topical Steroid Withdrawal vs Atopic Dermatitis Flare: Parsing the Differences with Brad Glick, DO, MPH
June 16th 2025
Revolutionizing Atopic Dermatitis (RAD)
RAD 2025: Glick spoke to Patient Care about the similarities between TSW and a flare of atopic dermatitis as well as specific signs now being identified d as characteristic.
Key Updates in Atopic Dermatitis for Primary Care
June 13th 2025
Revolutionizing Atopic Dermatitis (RAD)
Explore key insights from the 2025 Revolutionizing Atopic Dermatitis meeting, featuring expert interviews and the latest treatment advancements.
Expanding Access to Atopic Dermatitis Treatments for Children: A Conversation with Elizabeth Swanson, MD
June 13th 2025
Revolutionizing Atopic Dermatitis (RAD)
At RAD 2025, pediatric dermatologist Elizabeth Swanson, MD, discussed the value of focused AD education and anticipated label expansions for several treatments.
Q&A: JAK Inhibitor Safety in Context and the Rich Atopic Dermatitis Pipeline, with Leon Kircik, MD
June 13th 2025
Revolutionizing Atopic Dermatitis (RAD)
RAD 2025: Renowned AD investigator Kircik provides the history behind the class-wide black box warning, highlights JAK inhibitor efficacy, and toplines exciting AD research.
Why the OX-40/OX-40L Pathway Matters in Atopic Dermatitis—and What’s Next: A Q&A with Johann Gudjonsson, MD, PhD
June 12th 2025
Revolutionizing Atopic Dermatitis (RAD)
At RAD 2025, Johann Gudjonsson, MD, PhD, discussed the OX-40 pathway’s role in AD, genetic links to disease risk, and promising combination therapies in development.
A Close Look at Flexible Dosing Strategies for Atopic Dermatitis in Adults with Raj Chovatiya, MD, PhD, MSCI
June 12th 2025
Revolutionizing Atopic Dermatitis (RAD)
RAD 2025: Chovatiya toplines shifts in dosing strategies for topical, oral, and injectable AD therapy observed in both clinical trials and clinical practice.
Pediatric Atopic Dermatitis: Navigating Patient, Provider, Caregiver Connection with Peter Lio, MD
June 11th 2025
Revolutionizing Atopic Dermatitis (RAD)
RAD 2025. Peter Lio, MD, shares details from his presentation on shared decision making when treating children with atopic dermatitis.
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD
June 11th 2025
Revolutionizing Atopic Dermatitis (RAD)
RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.